openPR Logo
Press release

Genital Warts Pipeline Outlook 2025: Insights Into Therapies, Research, and Market Potential

09-11-2025 01:02 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: ABNewswire

Genital Warts Pipeline Outlook 2025: Insights Into Therapies,

DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Genital Warts Treatment Landscape. Click here to read more @ Genital Warts Pipeline Outlook [https://www.delveinsight.com/sample-request/genital-warts-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Genital Warts Pipeline Report

* On 11 August 2025, Merck Sharp & Dohme LLC announced a study includes a Base Study to assess efficacy and safety of V503, and an Extension Study. Participants who received placebo in the Base Study will be eligible to receive V503 vaccine on Day 1, Month 2, and Month 6 of the Extension Study. Participants who received less than 3 doses of V503 in the Base Study will be offered the opportunity to complete the 3-dose regimen in the Extension Study.
* DelveInsight's Genital Warts pipeline report depicts a robust space with 30+ active players working to develop 30+ pipeline therapies for Genital Warts treatment.
* The leading Genital Warts Companies such as ViroXis Corporation, bioRASI, LLC, Verrica Pharmaceuticals Inc., Orgenesis, Heber Biotec, Cassiopea, Novan, Peritech Pharma, Novartis and others.
* Promising Genital Warts Pipeline Therapies such as Imiquimod, NVN1000 8% Gel, Polyphenon E (Veregen) 15% ointment, AP611074 5% gel, Picato, V501, Podofilox Gel 0.5% and others.

Discover groundbreaking developments in Genital Warts Therapies! Gain in-depth knowledge of key Genital Warts clinical trials, emerging drugs, and market opportunities @ Genital Warts Clinical Trials Assessment [https://www.delveinsight.com/sample-request/genital-warts-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Genital Warts Emerging Drugs Profile

* VP-102: Verrica Pharmaceuticals

Verricas lead product candidate, VP-102, is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin (0.7% w/v) delivered via a single-use applicator that allows for precise topical dosing and targeted administration. Verrica is developing VP-102 for the treatment of common warts and external genital warts, three of the most common viral skin diseases in medical dermatology.

* SB206: Novan

Novan is developing SB206 as a topical antiviral gel for the treatment of viral skin infections, including external genital warts (EGW) caused by human papillomavirus (HPV). SB206 exhibited a dose responsive pharmacologic effect with complete inhibition of papilloma growth compared to topical imiquimod in an in vivo model. NVN1000, the active pharmaceutical ingredient in SB206, exhibited a dose dependent decrease in HPV viral replication in human raft cell culture model.

* CB-06-02: Cassiopea

CB-06-02, a NCE, immune modulator is being developed for the treatment of genital warts. Cassiopea believes it is the first potential treatment for this condition based on tellurium, a rare element. It acts as a low-toxicity immunomodulator in supporting the natural immune response against Human Papilloma Virus, or HPV. Based on the drug profiling Cassiopea has performed to date, the Company believes CB-06-02 has the potential to have a faster onset of action and a lower recurrence rate than currently available treatments.

The Genital Warts Pipeline Report Provides Insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Genital Warts with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Genital Warts Treatment.
* Genital Warts Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Genital Warts Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Genital Warts market

Stay informed about the Genital Warts pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Genital Warts Unmet Needs [https://www.delveinsight.com/sample-request/genital-warts-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Genital Warts Companies

ViroXis Corporation, bioRASI, LLC, Verrica Pharmaceuticals Inc., Orgenesis, Heber Biotec, Cassiopea, Novan, Peritech Pharma, Novartis, and others.

Genital Warts pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Infusion
* Intradermal
* Intramuscular
* Intranasal
* Intravenius
* Oral
* Parenteral
* Subcutaneous
* Topical.
* Molecule Type

Genital Warts Products have been categorized under various Molecule types such as

* Gene therapies
* Small molecule
* Vaccines
* Polymers
* Peptides
* Monoclonal antibodies
* Product Type

Transform your understanding of the Genital Warts Pipeline! See the latest progress in drug development and clinical research @ Genital Warts Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/genital-warts-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Genital Warts Pipeline Report

* Coverage- Global
* Genital Warts Companies- ViroXis Corporation, bioRASI, LLC, Verrica Pharmaceuticals Inc., Orgenesis, Heber Biotec, Cassiopea, Novan, Peritech Pharma, Novartis and others.
* Genital Warts Pipeline Therapies- Imiquimod, NVN1000 8% Gel, Polyphenon E (Veregen) 15% ointment, AP611074 5% gel, Picato, V501, Podofilox Gel 0.5% and others.
* Genital Warts Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Genital Warts Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay Ahead in Research-Access the Full Genital Warts Pipeline Analysis Today! @ Genital Warts Drugs and Companies [https://www.delveinsight.com/sample-request/genital-warts-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

* Introduction
* Executive Summary
* Genital Warts: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Genital Warts - DelveInsight's Analytical Perspective
* In-depth Commercial Assessment
* Genital Warts Collaboration Deals
* Late Stage Products (Phase III)
* Drug Name: Company Name
* Mid-Stage Products (Phase II)
* VP-102: Verrica Pharmaceuticals
* SB206: Novan
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Drug Name: Company Name
* Pre-clinical and Discovery Stage Products
* Drug Name: Company Name
* Inactive Products
* Genital Warts Key Companies
* Genital Warts Key Products
* Genital Warts- Unmet Needs
* Genital Warts- Market Drivers and Barriers
* Genital Warts- Future Perspectives and Conclusion
* Genital Warts Analyst Views
* Genital Warts Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=genital-warts-pipeline-outlook-2025-insights-into-therapies-research-and-market-potential]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/genital-warts-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Genital Warts Pipeline Outlook 2025: Insights Into Therapies, Research, and Market Potential here

News-ID: 4178167 • Views:

More Releases from ABNewswire

Ridiculously You Podcast Expands Casting Call for Bold Creatives, Innovators, and Women in Business
Ridiculously You Podcast Expands Casting Call for Bold Creatives, Innovators, an …
The Ridiculously You Podcast, hosted by award-winning speaker and best-selling author Julie May, is expanding its casting call in October for Women's Small Business Month. The show is seeking bold creatives and innovators including Disney Imagineers, Broadway performers, Lego Master Builders, Cirque du Soleil acrobats, Olympians, nonprofit founders, and entrepreneurs with disruptive ideas. Guests will receive a professional media kit with 10 to 20 captioned clips for reels and shorts. The
Uplers Highlights 2025 Trend: Brands Compete to Hire Graphic Designers With Advanced AI Skills
Uplers Highlights 2025 Trend: Brands Compete to Hire Graphic Designers With Adva …
The design industry is entering a new era in 2025 and the years to come. Creativity and artificial intelligence are merging to reshape how visual content is being produced. For brands, this no longer is a trend to monitor, instead it's a race to secure the right and skilled talent. Companies are fiercely competing to hire graphic designers who can harness AI tools to deliver innovation, speed, and consistency across
Inside Uplers Latest Report: What Companies Should Know About Angular Developer Pay and Demand
Inside Uplers Latest Report: What Companies Should Know About Angular Developer …
Angular continues to be one of the widely adopted front-end frameworks for dynamic and scalable app development. With digital products becoming increasingly complex, global hiring managers are continuing to face the challenge of finding Angular talent for balancing cost and availability. In response to this, Uplers is publishing new salary insights based on the evolving hiring trends for supporting companies in shaping their competitive strategies to hire Angular developers [https://www.uplers.com/hire-angularjs-developers/]. The
The Moss Way: Unlocking the True Power of Irish Sea Moss for Modern Wellness
The Moss Way: Unlocking the True Power of Irish Sea Moss for Modern Wellness
London, United Kingdom - 7 Oct, 2025 - As the wellness industry evolves, a growing number of people are turning back to nature's timeless remedies - and few are as powerful or as misunderstood as Irish Sea Moss. Leading this natural health renaissance is The Moss Way, a UK-based wellness brand redefining what it means to nourish the body with pure, sustainably sourced superfoods. With a focus on authenticity, science,

All 5 Releases


More Releases for Genital

Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead
Rising Sexual Health Awareness To Drive Genital Herpes Market Growth: A Key Driv …
The Genital Herpes Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]. What Is the Current Genital Herpes Market Size and Its Estimated Growth Rate? The genital herpes market has experienced strong growth in recent years. It will grow from $2.19 billion in 2024 to $2.34 billion
Rising Sexually Transmitted Infection (STI) Rates Propel Growth In Genital Warts …
The Genital Warts Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]. What Is the Genital Warts Market Size and Projected Growth Rate? The genital warts market has grown strongly in recent years. It is set to increase from $1.97 billion in 2024 to $2.08 billion in
Genital Warts Market - Revolutionizing Intimate Care: Transforming the Genital W …
Newark, New Castle, USA: The "Genital Warts Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors. Genital Warts Market: https://www.growthplusreports.com/report/genital-warts-market/8677 This latest report researches the industry structure, sales, revenue,
Genital Herpes - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Genital Herpes - Pipeline Review, H1 2017 to its growing collection of premium market research reports. Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Genital Herpes - Pipeline Review, H1 2017, provides an overview of the Genital Herpes (Infectious Disease) pipeline landscape. Genital herpes is a common sexually transmitted infection that affects both men and women. Genital herpes is caused
Genital Herpes - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Thyroid Cancer - Pipeline Review, H1 2017 to its growing collection of premium market research reports. Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Thyroid Cancer – Pipeline Review, H1 2017, provides an overview of the Thyroid Cancer (Oncology) pipeline landscape. Thyroid cancer is a cancer that starts in the thyroid gland. Symptoms include lump that can be felt through